Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Intercept Pharmaceuticals Withdraws Liver Disease Drug Ocaliva from US Market Following FDA Request

Intercept Pharmaceuticals Withdraws Liver Disease Drug Ocaliva from US Market Following FDA Request

Intercept Pharmaceuticals has announced the withdrawal of its liver disease drug Ocaliva (obeticholic acid) from the US market, marking a significant setback for the company and its efforts to treat primary biliary cholangitis (PBC). The decision comes after years of regulatory challenges and follows a direct request from the Food and Drug Administration (FDA).

NoahAI News9/12/2025
Private Equity Firms Make Major Moves in European Generics Market

Private Equity Firms Make Major Moves in European Generics Market

Chicago-based investment firm GTCR has agreed to acquire Zentiva, a Prague-based generics manufacturer, from Advent International in a deal valued at €4.1 billion ($4.8 billion). The transaction, expected to close in early 2026, marks another significant private equity investment in Europe's generic medicines sector.

NoahAI News9/12/2025
Epocrates Launches AI-Powered Assistant for Medication Prescribing

Epocrates Launches AI-Powered Assistant for Medication Prescribing

Epocrates, the renowned drug reference and clinical decision-support app owned by athenahealth, has unveiled a groundbreaking AI assistant feature designed to revolutionize medication prescribing decisions for healthcare professionals. This latest development marks a significant step forward in the integration of artificial intelligence into clinical practice, offering clinicians quick and accurate drug information at the point of care.

NoahAI News9/12/2025
Capsida Biotherapeutics Pauses Gene Therapy Trial Following Patient Death

Capsida Biotherapeutics Pauses Gene Therapy Trial Following Patient Death

Capsida Biotherapeutics, a California-based biotech company, has voluntarily paused its phase 1/2 clinical trial for CAP-002, a gene therapy targeting STXBP1 encephalopathy, following the death of the first patient enrolled in the study. The company is now working to determine the root cause of this tragic event, which has sent ripples through the gene therapy community and raised questions about the safety of novel delivery methods.

NoahAI News9/12/2025
LB Pharmaceuticals Upsizes IPO to $285M, Breaking Biotech Listing Drought

LB Pharmaceuticals Upsizes IPO to $285M, Breaking Biotech Listing Drought

LB Pharmaceuticals has successfully launched its initial public offering (IPO) on the Nasdaq, raising $285 million in gross proceeds and marking the first biotech listing in months. The company, focused on central nervous system (CNS) therapeutics, has increased its offering from the initially proposed 16.7 million shares to 19 million shares, priced at $15 each.

NoahAI News9/12/2025
Novo Nordisk Announces Major Restructuring and Return-to-Office Mandate

Novo Nordisk Announces Major Restructuring and Return-to-Office Mandate

Novo Nordisk, the Danish pharmaceutical giant, has unveiled a series of significant changes under the leadership of its new CEO, Maziar Mike Doustdar. The company is implementing a substantial restructuring plan and introducing a mandatory return-to-office policy, marking a pivotal moment in its corporate strategy.

NoahAI News9/12/2025
Custom Gene Editor Shows Promise for Rare Vascular Disease Treatment

Custom Gene Editor Shows Promise for Rare Vascular Disease Treatment

A groundbreaking gene editing technique developed by researchers at Mass General Brigham in Boston has successfully corrected a mutation responsible for a rare and deadly blood vessel disease in mice, opening new avenues for treating genetic vascular disorders.

NoahAI News9/12/2025
Diana Health Secures $55M in Series C Funding to Expand Women's Health Programs

Diana Health Secures $55M in Series C Funding to Expand Women's Health Programs

Diana Health, a women's health practice network collaborating with hospitals, has successfully raised $55 million in a Series C funding round. This significant investment will fuel the company's expansion plans and enhance its innovative approach to women's healthcare.

NoahAI News9/12/2025
Amgen and Kyowa Kirin Report Positive Long-Term Safety Data for Atopic Dermatitis Drug

Amgen and Kyowa Kirin Report Positive Long-Term Safety Data for Atopic Dermatitis Drug

Amgen and Kyowa Kirin have announced encouraging long-term safety and efficacy results for their investigational antibody rocatinlimab in the treatment of atopic dermatitis. The data, derived from the Phase III ASCEND extension study, bolsters the drug's potential for regulatory approval and market launch.

NoahAI News9/10/2025
Leadership Shakeup at CDC Sparks Senate Hearing Amid Vaccine Policy Controversy

Leadership Shakeup at CDC Sparks Senate Hearing Amid Vaccine Policy Controversy

The Centers for Disease Control and Prevention (CDC) finds itself at the center of a political maelstrom as former top officials prepare to testify before the Senate following a high-profile leadership dispute. The controversy, which has raised questions about the agency's independence and decision-making processes, comes at a critical juncture for public health policy in the United States.

NoahAI News9/10/2025
Novo Nordisk Announces Major Restructuring, Cuts 9,000 Jobs Worldwide

Novo Nordisk Announces Major Restructuring, Cuts 9,000 Jobs Worldwide

Novo Nordisk, a leading pharmaceutical company, has unveiled a significant restructuring plan that includes the elimination of approximately 9,000 positions globally. This move, announced by new CEO Maziar Mike Doustdar, aims to generate annualized savings of around $1.25 billion through 2026 and redirect resources towards growth opportunities in diabetes and obesity treatments.

NoahAI News9/10/2025
Novo Nordisk Announces Major Restructuring, 9,000 Layoffs Amid Changing Obesity Market Landscape

Novo Nordisk Announces Major Restructuring, 9,000 Layoffs Amid Changing Obesity Market Landscape

Novo Nordisk, the Danish pharmaceutical giant, has unveiled a sweeping restructuring plan that includes laying off 9,000 employees globally, representing about 11% of its workforce. The move, announced by new CEO Maziar Mike Doustdar, aims to save approximately 8 billion Danish kroner ($1.3 billion) annually by the end of 2026 and address challenges in the increasingly competitive obesity drug market.

NoahAI News9/10/2025
«1...616263...67»